Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × pegfilgrastim × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Neutropenia 16 Triple Negative Breast Neoplasms 6 Breast Neoplasms, Male 6 Neoplasms 2 Lung Neoplasms 2 Inflammatory Breast Neoplasms 2 Febrile Neutropenia 2 Recurrence 1 Pancreatic Neoplasms 1 Pain 1 Ovarian Neoplasms 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Locally Advanced Breast Cancer 1 HER2-positive Breast Cancer 1 HER2-Positive Early Stage Breast Cancer 1 Fever 1 Early Stage Breast Cancer 1 Colorectal Neoplasms 1 Chemotherapy-Induced Febrile Neutropenia 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Diseases 1 Breast Cancer Female 1 Adenocarcinoma 1

Interventions

Trastuzumab 29 pyrotinib 15 pertuzumab 15 Docetaxel 13 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 4 neratinib 3 Ado-Trastuzumab Emtansine 3 trastuzumab deruxtecan 2 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03571633 2025-11-26

BREASTIMMU02

Centre Leon Berard

Phase 2 Active not recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡